



Independent Medical Education (IME)

Request for Proposals (RFP):

RFP Title	ADC Treatment Optimization & Care Team Activation Program: Enhancing Multidisciplinary Implementation in PROC
Grant Amount	Up to \$250,000 (Multi-support is preferred but not required)
Targeted Learners	Oncologists, gynecologic oncologists, nurses, pharmacists, infusion staff, APPs, and multidisciplinary care teams.
RFP Requirements	<ul style="list-style-type: none"> <li>• Summary</li> <li>• Needs Assessment               <ul style="list-style-type: none"> <li>○ Root Causes Detailed</li> </ul> </li> <li>• Educational Objectives (if applicable)</li> <li>• Agenda</li> <li>• Intended Audience</li> <li>• Outcomes level and description of intended outcomes plan/delivery</li> <li>• Description of Partnership and why (If Applicable)</li> <li>• Description of why chosen locations were prioritized for education (If a live activity or applicable).</li> </ul>
RFP Posting Date	May 11, 2026
Submission Deadline	June 8, 2026 <a href="https://www.steeprovinc.com">Genmab Grants &amp; Giving Portal (steeprovinc.com)</a>
RFP Decision	June 22, 2026
Expected Launch Date	Post ESMO
Interim Outcomes	4-6 months post launch
Final Outcomes	As appropriate to the activity
Educational Program Design	<p>Preference will be given to proposals that:</p> <ul style="list-style-type: none"> <li>• Focus on <b>multidisciplinary decision-making and coordination</b></li> <li>• Provide <b>practical implementation tools</b></li> <li>• Address <b>AE management (including but not limited to ocular toxicities, neuropathy, ILV) and dosing decisions</b></li> <li>• Include <b>workflow and care pathway optimization</b></li> <li>• Deliver <b>enduring toolkits</b></li> <li>• Produce outputs that influence practice-level or system-level decision frameworks</li> </ul>

### **Statement of Purpose:**

Effective implementation of ADC therapies requires coordinated decision-making across care teams.

Challenges include:

- AE recognition (including but not limited to ocular toxicities, neuropathy, ILV), management decisions, and prophylactic mitigation plans
- Dosing strategy selection
- Testing and workflow coordination
- Infusion readiness and care transitions
- Patient adherence and education

These challenges contribute to variability in treatment delivery and outcomes.

Genmab seeks IME initiatives that improve team-based clinical and operational decision-making.

### **Measurable Outcomes:**

- % of participants demonstrating improved AE management (Including but not limited to ocular toxicities, neuropathy, ILV) decisions in case-based scenarios
- % of care teams implementing standardized workflows for ADC delivery
- Improvement in multidisciplinary decision alignment (pre/post team-based cases)
- Follow-up assessment evaluating practice-level changes in care coordination and ADC implementation

### **References :**

- Modi S, et al. Antibody-drug conjugates: mechanisms and clinical application. *Nat Rev Clin Oncol*. 2021.
- Ogitani Y, et al. ADC toxicity mechanisms and management. *Clin Cancer Res*. 2016.
- NCCN Guidelines: Ovarian Cancer (latest version)
- Korde LA, et al. Multidisciplinary cancer care and outcomes. *J Oncol Pract*.

### **RFP Evaluation:**

Genmab is committed to supporting IME that advances beyond traditional awareness-based education. Priority will be given to programs that demonstrate measurable impact on clinical decision-making, practice behavior, and care delivery. Proposals must clearly articulate how educational interventions will translate into real-world changes, and how those changes will be assessed.

Genmab welcomes submissions for IME grants from educational providers who can meet the associated deadlines for the RFP as outlined above.

All submissions will be reviewed in accordance with internal Genmab Policies and Procedures. Genmab does not support the costs associated with responding to this RFP and adheres to Fair Market Value

(FMV) for those areas of the budget, when relevant. Genmab holds the right not to support any submissions based upon our internal review criteria.

All submissions to the RFP should be accredited by the relevant body (i.e. ACCME). Genmab observes and follows all external guidelines and policies related to the support of Continuing Medical Education including but not limited to the ACCME, OIG, and FDA.

Applications for this RFP should place any educational interventions within the stated targeted community oncology setting(s). No preferred educational intervention, partnership, or community oncology setting has been identified, nor will one be used to evaluate submissions to this RFP.

Genmab reserves the right to cancel all or part of this RFP at any time. In the event of cancellation, Genmab will communicate the cancellation to all applicants.

**Contact:**

For more information, please contact Cody Ortmann, Associate Director of Independent Medical Education at [coor@genmab.com](mailto:coor@genmab.com)